Premium
Pharmacokinetics of quinine in chronic liver disease.
Author(s) -
Auprayoon P.,
Sukontason K.,
NaBangchang K.,
Banmairuroi V.,
Molunto P.,
Karbwang J.
Publication year - 1995
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1995.tb05795.x
Subject(s) - pharmacokinetics , quinine , medicine , oral administration , drug , liver disease , chronic liver disease , pharmacology , gastroenterology , cirrhosis , pathology , malaria
The pharmacokinetics of quinine were investigated in a) six healthy male Thai subjects, and b) nine male Thai patients with a moderate degree of chronic liver disease, after a single oral dose of 600 mg quinine sulphate. tmax and t1/2.2 were significantly prolonged in patients (median [range] tmax 2 [1‐5] vs 1.6 [0.8‐2] h; t1/2,z 23.4 [17.4‐41.7] vs 9.7 [7.8‐17.2] h), and Vz/F was significantly larger (median [range] 4.21 [2.33‐15.87] vs 2.78 [1.49‐3.38] 1 kg‐1). Median (range) concentration of the plasma unbound Qn fraction collected from the patients at 4 h after drug administration was 17 (8.4‐17.8)% of total drug concentration.